A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
Open Access
- 25 June 1999
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 80 (10) , 1595-1598
- https://doi.org/10.1038/sj.bjc.6690568
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study.Journal of Clinical Oncology, 1997
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerAnnals of Oncology, 1996
- No standard treatment is available for advanced pancreatic cancerEuropean Journal Of Cancer, 1995
- Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreasInvestigational New Drugs, 1994
- Should further studies of chemotherapy be carried out in pancreatic cancer?European Journal Of Cancer, 1993
- Cytotoxicity and Antitumor Activity of 2′,2′-Difluorodeoxycytidine (Gemcitabine)Cancer Investigation, 1990
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Reporting results of cancer treatmentCancer, 1981